Organogenesis Holdings (ORGO) Aandelenoverzicht
Organogenesis Holdings Inc., een bedrijf in regeneratieve geneeskunde, ontwikkelt, produceert en verkoopt producten voor de geavanceerde wondverzorging en chirurgische en sportgeneeskunde markten in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
ORGO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Organogenesis Holdings Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$2.44 |
| 52 Week Hoogtepunt | US$7.08 |
| 52 Week Laag | US$2.04 |
| Bèta | 1.33 |
| 1 maand verandering | -8.27% |
| 3 maanden verandering | -1.21% |
| 1 Jaar Verandering | -24.46% |
| 3 jaar verandering | -28.66% |
| 5 jaar verandering | -85.66% |
| Verandering sinds IPO | -81.85% |
Recent nieuws en updates
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked
Summary Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges. Management anticipates a gradual turnaround through 2026, with a potential acceleration in Q4. ReNu, its knee injection with a novel MOA and blockbuster potential, is awaiting FDA approval of its pending BLA. Read the full article on Seeking Alpha
ORGO: Reimbursement Shakeout And Knee Osteoarthritis BLA Will Drive Future Upside
Analysts reduced their price target on Organogenesis Holdings to $3, citing reimbursement-driven structural shifts that could eventually benefit the company as smaller competitors exit. They also pointed to limited near-term revenue upside after management lowered guidance to reflect a steeper expected decline in 2026.Recent updates
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked
Summary Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026 guidance now calls for a 45–52% year-over-year revenue drop to $270–310 million. Market headwinds have intensified, with clinicians in some cases moving away from skin substitutes entirely, compounding ORGO's challenges. Management anticipates a gradual turnaround through 2026, with a potential acceleration in Q4. ReNu, its knee injection with a novel MOA and blockbuster potential, is awaiting FDA approval of its pending BLA. Read the full article on Seeking AlphaORGO: Reimbursement Shakeout And Knee Osteoarthritis BLA Will Drive Future Upside
Analysts reduced their price target on Organogenesis Holdings to $3, citing reimbursement-driven structural shifts that could eventually benefit the company as smaller competitors exit. They also pointed to limited near-term revenue upside after management lowered guidance to reflect a steeper expected decline in 2026.
ORGO: FDA Rolling BLA For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have maintained their $8.00 price target on Organogenesis Holdings, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Organogenesis completed a planned Type B meeting with the FDA, securing confirmation to begin a rolling Biologics License Application for ReNu, with the filing expected to start before the end of December (Key Developments).ORGO: FDA BLA Progress For Knee Osteoarthritis Will Support Bullish Outlook
Analysts have slightly trimmed their price targets on Organogenesis Holdings, citing updated assumptions that include a modestly higher discount rate, slightly stronger revenue growth and profit margin estimates, and a somewhat lower future P/E multiple. What's in the News Organogenesis Holdings reported a successful Type B meeting with the FDA that cleared the way to start a rolling Biologics License Application, or BLA, for its ReNu product, with filing planned before the end of December (Key Developments).ORGO: FDA Rolling Submission For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have nudged their price target on Organogenesis Holdings higher to US$8.00, citing slightly firmer assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Completed a planned Type B meeting with the FDA, receiving confirmation to initiate a rolling Biologics License Application for ReNu, targeted before the end of December (Key Developments).The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28%
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shareholders won't be pleased to see that the share price has had a very...Is Organogenesis Holdings (NASDAQ:ORGO) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...ORGO: Regulatory Momentum For Knee Osteoarthritis Therapy Will Support Bullish Outlook
Analysts have raised their fair value estimate for Organogenesis Holdings from US$7.00 to US$8.00, citing changes in the discount rate, revenue growth assumptions, profit margin expectations and future P/E estimates as key drivers of the updated price target. What's in the News Completed a planned Type-B meeting with the FDA, with confirmation to begin a rolling Biologics License Application (BLA) for ReNu before the end of December (Key Developments).ORGO: Upcoming Knee Osteoarthritis BLA Filing Will Drive Long Term Upside
Analysts have modestly lifted their price target on Organogenesis Holdings to 8.50 dollars from 8.50 dollars, reflecting slightly higher long term profitability and valuation assumptions despite essentially unchanged growth and fair value estimates. What's in the News Completed a planned Type B FDA meeting confirming the path to initiate a rolling Biologics License Application for ReNu for knee osteoarthritis before the end of December, which advances the regulatory strategy for this lead asset (Key Developments) Raised 2025 guidance and projected net product revenue between 500.0 million dollars and 525.0 million dollars, an increase of 4% to 9% year over year, with expected net income between 8.6 million dollars and 25.4 million dollars (Key Developments) Reported that the second Phase 3 randomized controlled trial of ReNu in knee osteoarthritis did not meet its primary endpoint for statistical significance, but showed numerical pain reduction improvements and maintained a favorable safety profile, supporting plans for an FDA BLA filing (Key Developments) Highlighted that ReNu has been evaluated in three large randomized controlled trials involving more than 1,300 patients and previously received FDA Regenerative Medicine Advanced Therapy designation for knee osteoarthritis, which reinforces its clinical and regulatory foundation (Key Developments) Valuation Changes Fair Value Estimate remained unchanged at 8.50 dollars per share, indicating a stable view of intrinsic equity value.ORGO: Upcoming Knee Osteoarthritis FDA Filing Will Support Future Share Price Expansion
Analysts have modestly raised their price target on Organogenesis Holdings to 8.50 dollars from 7.50 dollars, citing a slightly higher assumed future price to earnings multiple that more than offsets minor adjustments to the discount rate and margin assumptions. What's in the News Raised 2025 earnings guidance, expecting net product revenue of 500 million to 525 million dollars, up 4% to 9% year over year from 482 million dollars in 2024, with projected net income between 8.6 million and 25.4 million dollars (company guidance).Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Shares Bounce 27% But Its Business Still Trails The Industry
Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have had a really impressive month, gaining 27% after a shaky period...ORGO: Anticipated 2025 Guidance And Promising Data Will Support Share Price Expansion
Analysts have revised their price target for Organogenesis Holdings downward from $8.00 to $7.50. This reflects a tempered outlook based on updated forecasts for revenue growth and profit margins.CMS Reform And Capacity Expansion Will Unlock Long Term Value
With no change in key metrics such as Future P/E and Net Profit Margin, the consensus analyst price target for Organogenesis Holdings remains steady at $8.00. What's in the News Organogenesis updated full-year 2025 guidance: expects net product revenue between $480 million and $510 million (roughly flat to 6% growth) and net income (loss) ranging from a $6.4 million loss to a $16.4 million profit.Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Organogenesis Holdings Inc. ( NASDAQ:ORGO ) shares have been powering on, with a gain of...
LCD Delays And ReNu Progress Will Unlock Market Potential
Delay in LCDs implementation offers a chance to capitalize on demand, boosting near-term revenue and market share for key products.There's No Escaping Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Muted Revenues Despite A 69% Share Price Rise
The Organogenesis Holdings Inc. ( NASDAQ:ORGO ) share price has done very well over the last month, posting an...Organogenesis: Lurking Disruption With Recovery To Follow
Summary Medicare reimbursement issues expected for certain of Organogenesis' skin substitute projects disrupting revenues in 2025. Major catalyst is expected for ORGO with BLA filing in late 2025. Liquidity is adequate and excellent potential for acquisition on expected pullbacks. Read the full article on Seeking AlphaWhy Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong...We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope
Key Insights Organogenesis Holdings to hold its Annual General Meeting on 20th of June Salary of US$908.7k is part of...Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst
Summary Organogenesis has two disproportionate segments, with Surgical and Sports Medicine making up a small portion of revenues. The company's pipeline candidate, ReNu, has the potential to boost Surgical and Sports Medicine revenues. In recent years, Organogenesis has generated inconsistent earnings and may not need to raise cash before launching ReNu. Read the full article on Seeking AlphaInvestors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality
Organogenesis Holdings Inc.'s ( NASDAQ:ORGO ) recent soft profit numbers didn't appear to worry shareholders, as the...Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Rendement voor aandeelhouders
| ORGO | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 4.3% | 1.3% | 1.4% |
| 1Y | -24.5% | 31.4% | 25.7% |
Rendement versus industrie: ORGO presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 31.4 % opleverde.
Rendement versus markt: ORGO presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 25.7 % opleverde.
Prijsvolatiliteit
| ORGO volatility | |
|---|---|
| ORGO Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: ORGO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van ORGO is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| n/a | 854 | Gary Gillheeney | organogenesis.com |
Organogenesis Holdings Inc., een bedrijf in regeneratieve geneeskunde, ontwikkelt, produceert en verkoopt producten voor geavanceerde wondverzorging, chirurgie en sportgeneeskunde in de Verenigde Staten. De producten voor geavanceerde wondverzorging omvatten Affinity en Novachor, allograften van placenta's uit amnion en chorion voor gebruik bij de verzorging van chronische en acute wonden als beschermende barrières en scaffolds van de extracellulaire matrix (ECM); Apligraf, een bio-engineered huidsubstituut met twee lagen voor de behandeling van veneuze beenzweren en diabetische voetzweren (DFU); Dermagraft, een huidsubstituut gekweekt uit menselijke dermale fibroblasten voor de behandeling van DFUs; NuShield, een gedehydrateerd placentaal allograft en chirurgische barrière om een beschermende barrière en ECM-steiger te bieden ter ondersteuning van de natuurlijke genezing; PuraPly Antimicrobial (AM) en PuraPly SX, antimicrobiële barrières voor de behandeling van open wonden in chirurgische omgevingen; en CYGNUS Dual, VIA Matrix en SimpliMax, placentale weefseltransplantaten voor de behandeling van chronische en acute wonden die bij kamertemperatuur kunnen worden bewaard. Het bedrijf levert ook PuraPly MZ, een gemicroniseerde versie van PuraPly voor de behandeling van open wonden in chirurgische omgevingen; PuraForce, een bio-engineered chirurgische matrix van varkenscollageen voor gebruik in toepassingen ter versterking van weke delen; FortiShield, een biosynthetische wondmatrix voor gebruik als een tijdelijke beschermende bedekking; en TransCyte, een bio-engineered weefselschavot dat de genezing van brandwonden bevordert.
Organogenesis Holdings Inc. Samenvatting
| ORGO fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$313.97m |
| Inkomsten(TTM) | -US$14.55m |
| Inkomsten(TTM) | US$514.70m |
Is ORGO overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ORGO resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$514.70m |
| Kosten van inkomsten | US$134.39m |
| Brutowinst | US$380.31m |
| Overige uitgaven | US$394.86m |
| Inkomsten | -US$14.55m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.11 |
| Brutomarge | 73.89% |
| Nettowinstmarge | -2.83% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde ORGO op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/21 21:06 |
| Aandelenkoers aan het einde van de dag | 2026/06/18 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Organogenesis Holdings Inc. wordt gevolgd door 8 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Michael Gorman | BTIG |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Richard Newitter | Leerink Partners LLC |